Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 7/20 | 0.46 |
| ▸ | KDR | P35968 | 7/20 | 0.46 |
| ▸ | JAK2 | O60674 | 4/20 | 0.42 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 3/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29857648 | 1.00 | PDGFRB (0.46) | PDGFRBKDRJAK2MAP3K12MET | |
| SCHEMBL26916323 | 1.00 | PDGFRB (0.46) | PDGFRBKDRJAK2MAP3K12MET | |
| SCHEMBL29857797 | 1.00 | PDGFRB (0.46) | PDGFRBKDRJAK2MAP3K12MET | |
| SCHEMBL10215045 | 1.00 | PDGFRB (0.46) | PDGFRBKDRJAK2MAP3K12MET | |
| SCHEMBL29857806 | 0.90 | JAK2 (0.42) | PDGFRBKDRJAK2MAP3K12AAK1 | |
| SCHEMBL26917195 | 0.90 | JAK2 (0.42) | PDGFRBKDRJAK2MAP3K12AAK1 | |
| SCHEMBL26916630 | 0.90 | JAK2 (0.42) | PDGFRBKDRJAK2MAP3K12AAK1 | |
| SCHEMBL26916637 | 0.90 | JAK2 (0.42) | PDGFRBKDRJAK2MAP3K12AAK1 | |
| SCHEMBL29857513 | 0.90 | JAK2 (0.42) | PDGFRBKDRJAK2MAP3K12AAK1 | |
| SCHEMBL26916586 | 0.89 | PDGFRB (0.39) | PDGFRBKDRJAK2MAP3K12MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167627-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | PDGFRB 2462/4885KDR 972/4885JAK2 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.